✨ Free AI Report
Century Therapeutics, Inc.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research Century Therapeutics, Inc.
Company Research

Century Therapeutics, Inc.: Business Overview, Financials & Competitive Analysis

Century Therapeutics (NASDAQ: IPSC) is a biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies for autoimmune diseases, including type 1 diabetes, and cancer. The company has cre...

Analyst-debate audio for Century Therapeutics, Inc.

AskCyborg analysts argue the bull and bear cases for Century Therapeutics, Inc. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
4/ 10Mixed

Cyborg Score thesis

Early-stage iPSC cell therapy developer with differentiated platform for autoimmune and oncology indications, but limited...

Read the full analyst-debate transcript →
Industry Stem Cell Therapy
5 named competitors
3 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: September 21, 2026
AI-Verified Research
30+ Page Report

Get the Latest Century Therapeutics, Inc. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Century Therapeutics, Inc. Overview

Pro stress-test →

Century Therapeutics (NASDAQ: IPSC) is a biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies for autoimmune diseases, including type 1 diabetes, and cancer. The company has created an allogeneic cell therapy platform that includes induced pluripotent stem cells (iPSCs), differentiation know-how to generate immune effector cells from iPSCs, and CRISPR gene editing to incorporate multiple transgenes and remove target genes.

Strategic Profile

Pro stress-test →

The company is focused on developing transformative allogeneic cell therapies to create products for the treatment of both solid tumor and hematological malignancies and autoimmune diseases. Clinical progress includes updated preliminary data expected in 2026 from the ongoing CARAMEL study, and an anticipated IND submission for CNTY-813 (lead beta islet cell therapy for type 1 diabetes) in Q4 2026 to support initial clinical data in H2 2027.

Competitive Landscape

Pro stress-test →

Fate Therapeutics is identified as a direct competitor, also operating in cell therapy. The market includes multiple companies developing iPSC-derived and CAR-T/CAR-iNK cell therapies for cancer and autoimmune indications. Century's differentiation centers on its allogeneic iPSC platform with gene editing capabilities and focus on both oncology and autoimmune diseases.

Industry Context

Century Therapeutics, Inc. operates in Stem Cell Therapy.

Key facts

Founded: 2018 · Headquarters: Philadelphia, US · Employees: 78 · Revenue: Estimated $0M (pre-revenue, clinical stage) · Market cap: $388M

What the analysts stress-tested

The top findings that survived the multi-agent debate for Century Therapeutics, Inc..

  • Lead candidate CNTY-101 is a CAR-iNK cell therapy with six precision gene edits currently in Phase I clinical trials for patients with B-cell mediated autoimmune diseases, positioning the company in the emerging CAR-iNK cell therapy space.
  • CNTY-813 preclinical data demonstrate high potency for functional glucose control and protection against immune rejection, with maintenance of normoglycemia in animal models for over 6 months and GMP manufacturing capability established.

Recent developments

Material events tracked by the AskCyborg corpus.

  • January 2026Private placement fundraising of approximately $106.2M completed
  • 2026CARAMEL investigator-sponsored trial interim data expected from Phase 1/2 CNTY-101 study
  • +1 moreTrack every material event for Century Therapeutics, Inc. as it happens. Explore monitoring →
Get alerted when Century Therapeutics, Inc. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

Fate TherapeuticsAllogeneic cell therapy for cancer and hematologic malignancies→Allogene TherapeuticsAllogeneic CAR-T cell therapy for cancer→Celyad OncologyCell therapy for hematologic malignancies and solid tumors→Caribou BiosciencesCRISPR-based cell therapy for cancer→Poseida TherapeuticsGene-edited cell therapy for cancer and genetic diseases→

Compare Century Therapeutics, Inc. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Century Therapeutics, Inc. operates in Stem Cell Therapy. See how the rest of the sector scores on the Cyborg framework.

Browse Stem Cell Therapy research →
NEW · MCP server

Ask your AI assistant about Century Therapeutics, Inc.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Century Therapeutics, Inc. and its top competitor on Cyborg Score”
“What did Century Therapeutics, Inc. do this quarter?”
“Is Century Therapeutics, Inc. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg builds confidence

⚔

Analyst debate, not single-author opinion

Every report is stress-tested by a panel of AI analysts arguing across 11 dimensions. The output is the part of the case that survived pushback.

📊

Recalibrated weekly

The Cyborg Score is recomputed weekly against fresh data. Recent material developments are continuously tracked and surfaced.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The same company gets the same score from any analyst running the framework.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, news flow, and proprietary analyst signals. Read the methodology →

Frequently asked questions

What does Century Therapeutics, Inc. do?+
Century Therapeutics (NASDAQ: IPSC) is a biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies for autoimmune diseases, including type 1 diabetes, and cancer. The company has cre...
What is Century Therapeutics, Inc.'s Cyborg Score?+
Century Therapeutics, Inc. has a Cyborg Score of 4/10 (Mixed). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Century Therapeutics, Inc.'s main competitors?+
Named competitors include Fate Therapeutics, Allogene Therapeutics, Celyad Oncology, Caribou Biosciences. The full competitive landscape is in the AskCyborg report.
How can I get the full Century Therapeutics, Inc. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Century Therapeutics, Inc. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Century Therapeutics, Inc. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

Top-scored companies on AskCyborg

The strongest performers across the analyst-debate framework.

9Advantest Corporation9Anthropic9Apple Inc.9Applied Materials, Inc.9Arista Networks9Aritzia Inc.9ASML Holding N.V.9BAE Systems plc9Barrick Mining Corporation9Berkshire Hathaway Inc.